Clinical trial NCT03537248: A Safety and Effectiveness Study of a New Multi-Purpose Contact Lens Care Solution
Official title: Clinical Safety and Effectiveness of ASP-57 Multi-Purpose Contact Lens Care Solution Compared to a Marketed Contact Lens Solution
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Contact Lens Wear
Lead sponsor: Asepticys LLC
Sponsor class: INDUSTRY
First posted: 2018-05-25
Enrollment: 315
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate the safety and effectiveness of ASP-57 Multi-Purpose contact lens solution (Test) compared to ReNu® Multiplus Contact Lens Solution (Control) when used by habitual contact lens wearers to bilaterally clean and disinfect their contact lenses for approximately 3 months (12 weeks).

Detailed description: Approximately 330 subjects (660 eyes) will be enrolled in this 3 month (12 week) controlled, parallel group, masked, randomized study at approximately 15 investigative sites in the United States. Subjects will be randomized 2:1 to receive either Asepticys ASP-57 Multi-Purpose Solution or ReNu® Multiplus Contact Lens Solution (Control) respectively. Both Test and Control solution will be used with a rub care regimen.

Eligibility criteria: Inclusion Criteria:

1. Subjects age ≥ 18 years on the date of informed consent.
2. All subjects must provide signed written consent prior to participation in any study related procedures.
3. Successful history of wear of the one of the following lens types (toric and multifocal lenses of the specified lens type are allowed) in both eyes during the past 3 months, and history of at least 5 consecutive days of successful daily wear in both eyes prior to Visit 1:

   * All Bausch \& Lomb PureVision lens types
   * All Alcon Air Optix lens types
   * All CooperVision Biofinity lens types
   * All Vistakon Acuvue Oasys lens types
   * Any conventional hydrogel Group IV lens
4. Vision correctable through spherocylindrical refraction to 32 letters (0.3 logMAR) or better (distance, high contrast) in each eye.
5. Clear central corneas and free of any anterior segment disorders
6. Habitual use of a Multi-Purpose Solution for cleaning, disinfecting, and storage of lenses.
7. Lens correction in both eyes is required and the same brand of lens is worn in each eye.
8. Agree to wear study lenses in both eyes on a daily wear basis, with lenses removed every night (not slept in) throughout the study period and no lens or pair of lenses worn for longer than 2 weeks.
9. Able and willing to comply with all care regimen and follow-up study procedures.

Exclusion Criteria:

1. Females of childbearing potential (not surgically sterilized or postmenopausal) if any one of the following conditions are met:

   * currently pregnant,
   * plan to become pregnant during the study,
   * are breast-feeding.
2. Wear of gas permeable contact lenses within the last 30 days.
3. Wear of polymethylmethacrylate lenses within the last 3 months.
4. No topical ocular prescription medications may be administered during the study period. Ongoing use of non-preserved artificial tears up to 4 times daily (with no changes in frequency or brand) is allowed. Ongoing use of the rewetting drop the subject customarily uses (with no switch in brand or type) is also permitted during the study period.
5. Current systemic disease affecting ocular health or use of topical or systemic medications that, in the Investigator's opinion, could affect ocular physiology or lens performance.
6. Ocular astigmatism of 2.00 D or greater in either eye based on the contact lens prescription.
7. Grade 2 or greater finding on any slit-lamp scale and/or corneal infiltrates of any grade during slit-lamp examination at Screening.
8. Any finding during slit-lamp examination that, in the Investigator's opinion, interferes with contact lens wear.
9. Scar or neovascularization within the central 4 millimeters (mm) of the cornea. Minor peripheral corneal scarring (that does not extend into the central zone) is permitted, if in the Investigator's judgment, it does not interfere with contact lens wear.
10. Aphakia.
11. Amblyopia.
12. History of any corneal surgery.
13. Allergy to any component of the study solutions.
14. Participation in any clinical study within the 2 weeks prior to entry into this study.

Primary outcomes:
measure: Slit Lamp Findings
timeFrame: 3 months
measure: Visual Acuity
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: Lakeside Vision Center
state: California
city: San Diego
country: United States
facility: Complete Family Vision Care
state: California
city: Longwood
country: United States
facility: Sabal Eye Care
state: Florida
city: Maitland
country: United States
facility: Maitland Vision Center
state: Florida
city: Orlando
country: United States
facility: Vision Health Institute
state: Florida
city: Bloomington
country: United States
facility: Eye Care Associates
state: Illinois
city: Pittsburg
country: United States
facility: Kannarr Eye Care
state: Kansas
city: Shawnee Mission
country: United States
facility: Heart of America Eye Care
state: Kansas
city: Havre De Grace
country: United States
facility: Seidenberg Protzko Eye Associates
state: Maryland
city: Warrensburg
country: United States
facility: Insight Eyecare
state: Missouri
city: Athens
country: United States
facility: Drs Quinn, Foster & Associates
state: Ohio
city: Warwick
country: United States
facility: West Bay Eye
state: Rhode Island
city: Memphis
country: United States
facility: Optometry Group
state: Tennessee
city: Nashville
country: United States
facility: Optique Eyecare
state: Tennessee
Study officials:
References: